Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Allows Claims in Regulus Patent Application on miR-21

Premium

Regulus Therapeutics, a joint venture between Alnylam Pharmaceuticals and Isis Pharmaceuticals, said this week that the US Patent and Trademark Office has allowed claims in a patent application covering microRNA-21.

According to the company, the miRNA is linked to a variety of diseases including cancer, fibrosis, and heart disease. The application, from the so-called Tuschl-III patent series, also covers single-stranded and double-stranded antisense compounds complementary to miR-21, Regulus said.

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.